We study a positioning game prior to negotiations where each party invests into influential activities in order to raise voter support for their preferred bargaining outcome. The case chosen for our analysis is a bilateral monopoly where a purchaser meets a pharmaceutical firm and where the two negotiate on the price of a new and innovative medicine. We identify factors that influence on the negotiated price such as treatment effects of the new and the existing drug, production costs of the new drug, the price of the existing drug, the marginal cost of public funds and patient group size. Furthermore, it is shown that the negotiated price, depending on the characteristics of a political cost function with regard to the influential activitie...
In markets where buyers and suppliers negotiate, supplier costs, buyer willingness to pay, and compe...
Many important issues in business-to-business markets involve price discrimination and negotiated pr...
Many countries, including Australia, regulate the price consumers pay for pharmaceuticals. In this p...
We study a positioning game prior to negotiations where each party invests into influential activiti...
We study a positioning game prior to negotiations where each party invests into influential activiti...
This dissertation - with the exception of Chapter 2 and the Appendices to Chapter 2 - is published u...
We study the strategic interaction between the pricing decisions of a pharmaceutical firm and the re...
The issues at stake for determining the price of a drug are related to finding an "equitable" trade-...
This paper proposes a pricing model for health care markets wherein providers and patients play a Na...
Faced with a situation where the market is unstable and the political context is crucial, we propose...
The shape of cost functions significantly influences the solution of optimization problems related t...
In this article we examine the alliance timing trade-off facing both pharmaceutical and biotech firm...
Both to address unmet medical needs and to improve industry competitiveness, regulators in both the ...
The U.S. government’s recent but unusual push to negotiate drug prices has struck a chord with many ...
In markets where buyers and suppliers negotiate prices, supplier costs, buyer willingness-to-pay, an...
In markets where buyers and suppliers negotiate, supplier costs, buyer willingness to pay, and compe...
Many important issues in business-to-business markets involve price discrimination and negotiated pr...
Many countries, including Australia, regulate the price consumers pay for pharmaceuticals. In this p...
We study a positioning game prior to negotiations where each party invests into influential activiti...
We study a positioning game prior to negotiations where each party invests into influential activiti...
This dissertation - with the exception of Chapter 2 and the Appendices to Chapter 2 - is published u...
We study the strategic interaction between the pricing decisions of a pharmaceutical firm and the re...
The issues at stake for determining the price of a drug are related to finding an "equitable" trade-...
This paper proposes a pricing model for health care markets wherein providers and patients play a Na...
Faced with a situation where the market is unstable and the political context is crucial, we propose...
The shape of cost functions significantly influences the solution of optimization problems related t...
In this article we examine the alliance timing trade-off facing both pharmaceutical and biotech firm...
Both to address unmet medical needs and to improve industry competitiveness, regulators in both the ...
The U.S. government’s recent but unusual push to negotiate drug prices has struck a chord with many ...
In markets where buyers and suppliers negotiate prices, supplier costs, buyer willingness-to-pay, an...
In markets where buyers and suppliers negotiate, supplier costs, buyer willingness to pay, and compe...
Many important issues in business-to-business markets involve price discrimination and negotiated pr...
Many countries, including Australia, regulate the price consumers pay for pharmaceuticals. In this p...